InvestSMART

Vectus Biosystems Limited (ASX:VBS)

ALERT: Price-sensitive ASX Announcement for VBS
Current share price for VBS : $0.120 -0.02 (-14.29%)+
Announcement
Release
30 Jan 2026 2:49PM
Price at Release
$0.140
Full Release
download
Summary
Vectus Biosystems Limited's Quarterly Activities and Appendix 4C Cash Flow Report for December 2025 highlights the execution of a binding agreement with XORTX for the sale of VB4-P5 Renal Small Molecule Compound, likely to provide Vectus with shares in XORTX. The company focuses on licensing opportunities for VB0004 and other compounds, while reducing operating costs after completing Phase Ib human trials. Cash-on-hand was reported at $330,000, sourced from an R&D cash-back claim, with additional liquidity planned through the XORTX transaction and a loan facility from Director Maurie Stang. Vectus continues to manage its expenses through premises relocation and deferred operational costs.
Key Points
  • Vectus Biosystems Limited executed a binding agreement with XORTX for the sale of its VB4-P5 Renal Small Molecule Compound.
  • The transaction with XORTX is expected to provide Vectus with a direct shareholding in the Canadian biotechnology company.
  • Vectus is exploring licensing opportunities for its lead compound VB0004 and other drug candidates.
  • The company has significantly reduced its operating expenses following the finalization of Phase Ib human clinical trials.
  • Cash-on-hand at the end of December 2025 was $330,000, with funds from the Australian Taxation Office's R&D cash-back claim.
  • Vectus has secured a loan facility of up to $450,000 from Director Maurie Stang, fully drawn as of 31 December 2025.
  • The company is actively pursuing licensing opportunities and potential partnerships to address future capital requirements.
  • Vectus has relocated to new premises to reduce costs and deferred certain significant operating costs through 2025 and 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.